Brief: KALA BIO Says Co Targeting Reporting Topline Safety, Efficacy Data From CHASE Phase 2b Clinical Trial By 2024 End
04/03/2024 12:41
March 4 (Reuters) - KALA BIO Inc KALA.O :
* KALA BIO: SEES REPORTING TOPLINE SAFETY FROM CORNEAL
HEALING
AFTER SECRETOME THERAPY PHASE 2B CLINICAL TRIAL EVALUATING
KPI-012 BY 2024 END
Source text for Eikon: ID:n0001558370-24-002313
Further company coverage: KALA.O
((Reuters.Briefs@thomsonreuters.com;))